THC, the primary psychoactive compound in cannabis, has a short but growing list of proven medical uses and several more where the evidence is promising but incomplete. Two uses have full FDA approval: treating nausea from chemotherapy and stimulating appetite in people with AIDS-related weight loss. Beyond those, THC shows moderate benefits for nerve pain, muscle spasticity in multiple sclerosis, and short-term sleep problems, though each comes with real trade-offs worth understanding.
How THC Works in the Body
Your brain already produces its own cannabis-like chemicals, called endocannabinoids, that plug into receptors throughout the nervous system. THC mimics these natural compounds by binding to the same receptors, particularly one called CB1, which is concentrated in the brain and spinal cord. When THC activates CB1 receptors, it alters how nerve cells release their chemical signals. Specifically, it dials down the release of certain neurotransmitters, which is why it can reduce pain signaling, ease muscle contractions, and suppress the nausea reflex.
This same mechanism explains both the therapeutic effects and the high. THC doesn’t target one system neatly. It influences pain circuits, mood regulation, appetite signaling, and memory processing all at once, which is why its medical benefits almost always come packaged with psychoactive side effects.
FDA-Approved Medical Uses
The FDA has approved a synthetic form of THC (sold as Marinol) for two specific conditions. The first is loss of appetite and weight loss in people with AIDS. The standard starting dose is 2.5 mg taken twice daily before meals. The second is nausea and vomiting caused by cancer chemotherapy, but only when conventional anti-nausea drugs have already failed. A second synthetic THC drug, nabilone, carries the same approval for chemotherapy nausea in both the US and Canada.
Results for appetite stimulation are modest. In cancer-related weight loss studies, only about 3% to 5% of patients on THC achieved more than a 10% increase in body weight. Some trials found average weight gains of around 1 kg. These numbers are meaningful for severely underweight patients but are not dramatic, and THC has not outperformed other appetite stimulants in head-to-head comparisons.
Nerve Pain
Chronic nerve pain, especially from injuries or surgery, is one of the better-studied uses of THC. In a randomized controlled trial, patients with post-traumatic or postsurgical nerve pain who inhaled cannabis containing 9.4% THC three times daily for five days saw their average pain drop from 6.1 to 5.4 on a 10-point scale. That 0.7-point reduction was statistically significant but modest compared to standard nerve pain medications like gabapentin (1.2-point reduction) and pregabalin (1.3 points).
THC is not a first-line pain treatment. It’s most often considered when people haven’t responded well to conventional options, or as a supplement to reduce reliance on opioids. The pain relief is real but limited, and it requires repeated dosing throughout the day.
Muscle Spasticity in Multiple Sclerosis
For people with MS, muscle stiffness and spasms are among the most disabling daily symptoms. A THC-containing mouth spray (nabiximols, sold as Sativex in some countries) has been studied extensively for this. Across five randomized trials involving over 1,100 participants, people using the spray were roughly 2.5 times more likely to report a meaningful reduction in spasticity compared to placebo. In absolute terms, about 216 more people per 1,000 experienced benefit with the spray than without it.
Regulatory bodies have responded differently to this evidence. The European Medicines Agency approved nabiximols in 2014 for moderate-to-severe MS spasticity that hasn’t responded to other treatments. British neurologists recommend it as a second-line option. Australia’s health department has issued similar guidance. The FDA, however, has not approved it, and American neurology guidelines support further research but stop short of endorsing it for clinical use.
Sleep: Short-Term Help, Long-Term Problems
THC’s effects on sleep follow a pattern that catches many people off guard. In the short term, it genuinely helps. It reduces the time it takes to fall asleep, increases total sleep time, and decreases the number of times you wake up during the night. It also increases deep sleep (slow-wave sleep), which is the most physically restorative stage. At the same time, it suppresses REM sleep, the stage associated with dreaming.
With regular use over weeks or months, these benefits reverse. Tolerance develops, and chronic users tend to show increased time to fall asleep (often over 30 minutes), more nighttime awakenings, and reduced total sleep. One sleep-lab study found that 78% of regular cannabis users had decreased overall sleep time, with poor sleep efficiency below 85% and an average of nearly 55 minutes of wakefulness after initially falling asleep. REM sleep also dropped to about 17.7% of total sleep, well below normal.
If you’re considering THC for sleep, the takeaway is that it may work for a short stretch but tends to worsen sleep quality the longer you use it.
PTSD Symptoms
THC’s ability to suppress REM sleep has drawn interest for one specific group: people with PTSD who experience recurring nightmares. Small clinical trials have found that THC and synthetic THC compounds reduce nightmares and improve sleep quality in PTSD patients. In one study, cannabis users with PTSD were over 2.5 times more likely to no longer meet diagnostic criteria for the condition after one year, largely because of significant reductions in hyperarousal symptoms like being easily startled, feeling on edge, and having difficulty sleeping.
These results are encouraging but based on small sample sizes. Larger, more rigorous trials are still needed before THC can be recommended as a standard PTSD treatment.
Glaucoma: Limited Usefulness
THC does lower eye pressure, which is the central problem in glaucoma. A sublingual THC spray reduced eye pressure by about 6.5 mmHg in one study, and oral THC produced reductions of 1 to 5 mmHg over treatment periods of one to nine months. But the effect wears off quickly, typically within two to six hours. Standard glaucoma medications provide steady, all-day pressure control with a single dose or two. To match that with THC, you would need to dose multiple times throughout the day and night, which means constant psychoactive effects and disrupted daily functioning. Most ophthalmology organizations do not recommend THC for glaucoma because existing drugs simply work better and longer.
The Dose Problem
One of THC’s trickiest properties is its biphasic dose response, meaning low and high doses produce opposite effects. Animal research has mapped this clearly: low doses of cannabinoids reduce anxiety by acting on nerve cells that use the excitatory neurotransmitter glutamate, while high doses increase anxiety by acting on nerve cells that use the inhibitory neurotransmitter GABA. In practical terms, a small amount of THC might calm you down, while a larger amount of the same product might trigger panic or paranoia.
This biphasic pattern shows up across multiple uses. Low doses tend to relieve pain, ease nausea, and promote relaxation. Higher doses are more likely to cause anxiety, impaired memory, and increased heart rate. There is no universal threshold where “helpful” tips into “harmful” because individual tolerance varies widely based on genetics, prior exposure, and the method of consumption.
Cognitive and Psychiatric Risks
THC is not risk-free, and the cognitive side effects are well documented. Brain imaging studies show that recent cannabis use is associated with reduced brain activation during working memory tasks. People perform worse on tests of working memory and a mental skill called theory of mind (the ability to understand what other people are thinking or feeling). These deficits appear in both occasional and heavy users, though they are more pronounced with heavier, longer-term use.
The psychiatric risks are also real. High doses of THC can trigger acute psychotic episodes, particularly in people with a personal or family history of psychosis. The same brain imaging research suggests that THC disrupts neural patterns in ways that overlap with the mechanisms seen in psychotic disorders. For people with a history of schizophrenia, bipolar disorder, or severe anxiety, THC carries meaningful risk that may outweigh its potential benefits.